Status:
UNKNOWN
The Effects of Preoperative Bevacizumab on Perioperative Complications
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions:
Colorectal Cancer
Lung Cancer
Eligibility:
All Genders
18-90 years
Brief Summary
This is a nationwide multicenter,retrospective,observational real-world study. 1. To assess the risk of perioperative complications in patients with tumor who received bevacizumab prior to unexpected...
Detailed Description
Avastin (bevacizumab) is a recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor(VEGF) in in vitro and in vivo ass...
Eligibility Criteria
Inclusion
- Patients with colorectal cancer and lung cancer who underwent unexpected operation from 01 Jan 2010 to 31 Dec 2019, and received bevacizumab within 6 weeks (including 6 weeks) before operation;
- Patients aged 18-90 years old;
- Complete clinical data related to important indicators, including preoperative baseline data, surgical information and perioperative prognosis information.
Exclusion
- Patients who used anti-angiogenic agents other than bevacizumab within 6 weeks prior to unexcepted operation.
Key Trial Info
Start Date :
April 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 31 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04788381
Start Date
April 1 2021
End Date
July 31 2021
Last Update
March 9 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China, 0571